vs
Side-by-side financial comparison of AVINO SILVER & GOLD MINES LTD (ASM) and Coherus Oncology, Inc. (CHRS). Click either name above to swap in a different company.
AVINO SILVER & GOLD MINES LTD is the larger business by last-quarter revenue ($21.0M vs $12.7M, roughly 1.7× Coherus Oncology, Inc.). AVINO SILVER & GOLD MINES LTD runs the higher net margin — 36.6% vs -295.3%, a 331.9% gap on every dollar of revenue. On growth, Coherus Oncology, Inc. posted the faster year-over-year revenue change (64.9% vs 44.0%). Over the past eight quarters, AVINO SILVER & GOLD MINES LTD's revenue compounded faster (51.1% CAGR vs -47.0%).
Avino Silver & Gold Mines Ltd is a Canada-based mining company engaged in the exploration, development, and production of precious and base metals, primarily silver, gold, and copper. It operates its flagship Avino Mine property in Durango, Mexico, with its metal products supplied to global industrial and commodity markets.
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
ASM vs CHRS — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.0M | $12.7M |
| Net Profit | $7.7M | $-37.6M |
| Gross Margin | 47.1% | 68.3% |
| Operating Margin | — | -359.9% |
| Net Margin | 36.6% | -295.3% |
| Revenue YoY | 44.0% | 64.9% |
| Net Profit YoY | 558.9% | 25.7% |
| EPS (diluted) | $0.05 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.7M | ||
| Q3 25 | $21.0M | $11.6M | ||
| Q2 25 | $21.8M | $10.3M | ||
| Q1 25 | $18.8M | — | ||
| Q3 24 | $14.6M | — | ||
| Q2 24 | $14.8M | $10.3M | ||
| Q1 24 | $12.4M | — | ||
| Q3 23 | $12.3M | $74.6M |
| Q4 25 | — | $-37.6M | ||
| Q3 25 | $7.7M | $-35.5M | ||
| Q2 25 | $2.9M | $297.8M | ||
| Q1 25 | $5.6M | — | ||
| Q3 24 | $1.2M | — | ||
| Q2 24 | $1.2M | $-12.9M | ||
| Q1 24 | $599.0K | — | ||
| Q3 23 | $-803.0K | $-39.6M |
| Q4 25 | — | 68.3% | ||
| Q3 25 | 47.1% | 67.8% | ||
| Q2 25 | 46.9% | 66.9% | ||
| Q1 25 | 56.1% | — | ||
| Q3 24 | 39.1% | — | ||
| Q2 24 | 31.8% | 82.4% | ||
| Q1 24 | 18.9% | — | ||
| Q3 23 | 19.2% | 56.1% |
| Q4 25 | — | -359.9% | ||
| Q3 25 | — | -383.1% | ||
| Q2 25 | — | -443.6% | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -384.9% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | -42.9% |
| Q4 25 | — | -295.3% | ||
| Q3 25 | 36.6% | -307.1% | ||
| Q2 25 | 13.1% | 2903.9% | ||
| Q1 25 | 29.8% | — | ||
| Q3 24 | 8.0% | — | ||
| Q2 24 | 8.4% | -125.5% | ||
| Q1 24 | 4.8% | — | ||
| Q3 23 | -6.5% | -53.2% |
| Q4 25 | — | $-0.34 | ||
| Q3 25 | $0.05 | $-0.31 | ||
| Q2 25 | $0.02 | $2.57 | ||
| Q1 25 | $0.04 | — | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $0.01 | $-0.11 | ||
| Q1 24 | $0.00 | — | ||
| Q3 23 | $-0.01 | $-0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $57.3M | $172.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $182.1M | $61.0M |
| Total Assets | $221.9M | $258.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $172.1M | ||
| Q3 25 | $57.3M | $191.7M | ||
| Q2 25 | $37.3M | $237.6M | ||
| Q1 25 | $26.6M | — | ||
| Q3 24 | $7.8M | — | ||
| Q2 24 | $5.3M | $159.2M | ||
| Q1 24 | $3.5M | — | ||
| Q3 23 | $1.9M | $131.1M |
| Q4 25 | — | $61.0M | ||
| Q3 25 | $182.1M | $87.8M | ||
| Q2 25 | $144.8M | $119.8M | ||
| Q1 25 | $132.3M | — | ||
| Q3 24 | $114.5M | — | ||
| Q2 24 | $112.2M | $-84.1M | ||
| Q1 24 | $107.8M | — | ||
| Q3 23 | $102.7M | $-133.6M |
| Q4 25 | — | $258.3M | ||
| Q3 25 | $221.9M | $516.5M | ||
| Q2 25 | $174.7M | $439.5M | ||
| Q1 25 | $157.7M | — | ||
| Q3 24 | $135.4M | — | ||
| Q2 24 | $133.7M | $674.9M | ||
| Q1 24 | $128.6M | — | ||
| Q3 23 | $123.5M | $583.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.3M | $-19.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.08× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-19.7M | ||
| Q3 25 | $8.3M | $-46.3M | ||
| Q2 25 | $8.3M | $-46.6M | ||
| Q1 25 | $758.0K | — | ||
| Q3 24 | $4.1M | — | ||
| Q2 24 | $1.1M | $59.7M | ||
| Q1 24 | $2.3M | — | ||
| Q3 23 | $-83.0K | $-54.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 2.92× | -0.16× | ||
| Q1 25 | 0.13× | — | ||
| Q3 24 | 3.55× | — | ||
| Q2 24 | 0.87× | — | ||
| Q1 24 | 3.92× | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASM
Segment breakdown not available.
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
